Voloridge Investment Management
NBIX icon

Voloridge Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Voloridge Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-45,736
Closed -$5.27M – 1304
2024
Q3 		$5.27M Buy
45,736
+29,918
+189% +$4.1M 0.02% 764
2024
Q2 		$2.18M Sell
15,818
-104,385
-87% -$14.3M 0.01% 930
2024
Q1 		$16.6M Buy
120,203
+98,194
+446% +$13.4M 0.06% 378
2023
Q4 		$2.9M Buy
+22,009
New +$2.53M 0.01% 742
2023
Q3 		– Sell
-11,347
Closed -$1.07M – 1532
2023
Q2 		$1.07M Sell
11,347
-98,409
-90% -$9.62M 0.01% 1109
2023
Q1 		$11.1M Buy
109,756
+74,129
+208% +$7.71M 0.06% 425
2022
Q4 		$4.26M Buy
+35,627
New +$4.17M 0.02% 701
2021
Q3 		– Sell
-32,103
Closed -$3.12M – 1786
2021
Q2 		$3.12M Buy
+32,103
New +$3.08M 0.02% 816
2021
Q1 		– Sell
-142,703
Closed -$13.7M – 1567
2020
Q4 		$13.7M Buy
142,703
+107,190
+302% +$10.4M 0.11% 213
2020
Q3 		$3.42M Buy
35,513
+27,414
+338% +$3.17M 0.03% 554
2020
Q2 		$988K Sell
8,099
-54,375
-87% -$6.01M 0.01% 853
2020
Q1 		$5.41M Sell
62,474
-60,797
-49% -$5.95M 0.16% 143
2019
Q4 		$13.3M Buy
+123,271
New +$12.9M 0.26% 87
2019
Q2 		– Sell
-22,971
Closed -$2.02M – 965
2019
Q1 		$2.02M Sell
22,971
-37,683
-62% -$3.15M 0.06% 291
2018
Q4 		$4.33M Buy
+60,654
New +$5.81M 0.2% 125
2018
Q3 		– Sell
-98,582
Closed -$9.69M – 410
2018
Q2 		$9.69M Buy
98,582
+50,903
+107% +$4.56M 0.26% 92
2018
Q1 		$3.95M Sell
47,679
-93,077
-66% -$7.86M 0.09% 190
2017
Q4 		$10.9M Buy
+140,756
New +$9.6M 0.24% 102
2015
Q3 		– Sell
-24,534
Closed -$1.17M – 365
2015
Q2 		$1.17M Buy
+24,534
New +$1.04M 0.06% 216

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Voloridge Investment Management's NBIX Position: Q4 2024 in Review

Voloridge Investment Management sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 45,736 shares — an estimated $5.27M sold.

Voloridge Investment Management first reported a position in NBIX in Q2 2015 and held it in 19 quarters. The position peaked at $16.6M in Q1 2024. 601 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • Voloridge Investment Management reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
  • Voloridge Investment Management sold 45,736 Neurocrine Biosciences shares in Q4 2024, an estimated $5.27M.
  • Voloridge Investment Management first reported a position in Neurocrine Biosciences in Q2 2015 and held it in 19 quarters.
  • Voloridge Investment Management's Neurocrine Biosciences position peaked at $16.6M in Q1 2024.
  • 601 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Voloridge Investment Management's 13F filing for Q4 2024, filed 14 Feb 2025.